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http://dx.doi.org/10.1016/j.bbmt.20Major concerns about radioimmunotherapy (RIT) administration early in the course of follicular lymphoma
(FL) are long-term toxicity and the theoretical impairment of hematopoietic stem cell (HSC) harvest, but few
data are available about mobilization rates after RIT. This study evaluates the impact of prior therapy with RIT
(yttrium-90 ibritumomab tiuxetan) and different chemotherapy regimens in all FL patients (N ¼ 103)
attempting HSC mobilization at our institution over the last 7 years. Sixty-nine patients received R-CHOP
(rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone) or CHOP-like regimens, 21 patients
received R-FM (rituximab-ﬂudarabine-mitoxantrone), and 13 patients received RIT before HSC mobilization.
Median CD34þ cell yield at ﬁrst mobilization was 7.2  106/kg in the R-CHOP group versus 4.3 in the R-FM
group versus 1.7 in the RIT group (P ¼ .02 R-CHOP versus R-FM; P < .0001 R-CHOP versus RIT; P < .02 R-FM
versus RIT). Although 8 of 13 patients initially failed to collect enough HSC after RIT, a second and/or salvage
harvest was successfully performed in 7 patients, with 10 of 13 patients (77%) ﬁnally undergoing autologous
stem cell transplantation (ASCT). No differences in engraftment kinetics were observed between the three
groups (R-CHOP versus R-FM versus RIT). Although mobilization was signiﬁcantly impaired in patients
previously treated with RIT, a salvage HSC harvest and ASCT after RIT were safe and feasible in most patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION showed the most potent single-agent activity against
Follicular lymphoma (FL), the most common form of
indolent B cell lymphoma in Western countries [1,2],
is characterized by a long natural history with multiple
relapses and remains incurable with current standard ther-
apeutic approaches [3,4]. Whereas the anti-CD20 antibody
rituximab has been broadly accepted as part of ﬁrst-line
therapy [5-9] or as maintenance therapy [10], there is
no standard ﬁrst-line chemotherapy, because an overall
survival advantage of one regimen over another has not
been demonstrated [11]. Because some reports underline
the potential of bone marrow damage [12,13] of ﬂudarabine-
containing regimens, with impairment in subsequent
hematopoietic stem cell (HSC) collection and increased risk
of secondary acute myeloid leukemias/myelodysplastic
syndromes [13], the R-CHOP (rituximab-cyclophosphamide-
doxorubicin-vincristine-prednisone) is widely used as
induction therapy.
In the relapsed/refractory setting, radioimmunotherapy
(RIT) is an effective and manageable treatment option, and
yttrium-90 ibritumomab tiuxetan and iodine I-131 tositu-
momab are currently approved in, respectively, Europe and
the United States for the treatment of relapsed/refractory or
transformed FL [14,15]. These radioimmunoconjugatesedgments on page 1700.
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13.09.004FL [16,17] with high and durable response rates if used as
ﬁrst-line therapy. The results of RIT with yttrium-90 ibritu-
momab tiuxetan in the setting of ﬁrst-line therapy consoli-
dation are also very promising, demonstrating a signiﬁcant
progression-free survival advantage over observation [18].
Also, several phase II trials conﬁrmed the feasibility and
efﬁcacy of RIT as consolidation treatment after ﬁrst-line
therapy [19-22]. On the other hand, autologous stem cell
transplantation (ASCT) is a suitable option for relapsed FL
patients [23-25]. Whereas front-line ASCT results in durable
remissions and superior progression-free survival compared
with standard therapy, to date available data do not support
the use of ASCT as ﬁrst-line consolidation, given the lack of
overall survival advantage [26-28].
Considering the natural history of FL, the importance of
appropriate drug choice and the placement of RIT and ASCT
in the disease course remains an issue, and to date the best
way to sequence available treatment strategies is still
undeﬁned. Major concerns about the widespread use of RIT
early in the disease course (as ﬁrst-line consolidation) are
long-term hematologic toxicity and the theoretically possible
irreparable damage to bone marrow function with impair-
ment of peripheral stem cell harvest and thus ASCT. Although
RIT administration after ASCT has been demonstrated to be
safe and feasible [29], no data are available about peripheral
blood stem cell (PBSC) mobilization rates after RIT exposure,
and the available reports are anecdotal [30]. The aim of this
monocentric study is to analyze the impact of prior RIT
administration on PBSC mobilization and harvest and on the
outcome of subsequent ASCT. The impact of the type of priorTransplantation.
Figure 1. General study design. LVEF, left ventricular ejection fraction; PFT,
pulmonary function test; PR, partial response.
E. Derenzini et al. / Biol Blood Marrow Transplant 19 (2013) 1695e17011696regimens and number of previous lines of therapy were
evaluated in all FL patients (N ¼ 103) who underwent PBSC
mobilization at our institution from January 2005 to
December 2012.
METHODS
Data Source, Assessments, and Study Endpoints
Data from all FL patients who attempted PBSCmobilization from 2005 to
2012 were prospectively collected, and the impact of previous RIT and other
chemotherapy regimens given earlier in the disease course on HSC collec-
tion was retrospectively evaluated. In our clinical practice, stem cell
collection and ASCT was attempted in patients younger than 65 years of
age with adequate performance status (Eastern Cooperative Oncology
Group  2) at disease relapse or in those patients who did not achieve
a complete response after ﬁrst-line chemoimmunotherapy. Thirteen
patients included in a phase II study received ASCT as consolidation in ﬁrst
complete response. RIT with yttrium-90 ibritumomab tiuxetan was largely
used preferentially in elderly patients (65 years) with relapsed/refractory
disease or in those patients who refused or were unﬁt for ASCT. RIT was
given as consolidation after ﬁrst-line treatment to 47 patients enrolled in 2
phase II studies and 1 phase III randomized trial [1-3].
The study algorithm is shown in Figure 1. The primary endpoint was to
describe the impact of previous RIT compared with different prior treatment
regimens (R-CHOP/CHOP-like regimens and R-FM [rituximab-ﬂudarabine-
mitoxantrone]) on PBSC mobilization and on the safety and efﬁcacy of
subsequent remobilization/collection procedures in FL patients. The
secondary endpoint was to evaluate differences in neutrophil and platelet
(PLT) engraftment kinetics after ASCT across the 3 groups. Neutrophil
engraftment was deﬁned as the ﬁrst day with an absolute neutrophil count
(ANC) > .5  103/mL. PLT engraftment was deﬁned as the ﬁrst day with a PLT
count > 20  103/mL.
Treatment Protocols
Patients were treated with the following chemoimmunotherapy regi-
mens either at disease onset or at relapse, according to our institutional
guidelines: R-CHOP, R-MACOP-B (rituximab, cyclophosphamide, doxoru-
bicin, methotrexate, vincristine, bleomycin, prednisone), R-FM, and R-CVP
(rituximab, cyclophosphamide, vincristine, prednisone) were given as
previously described [11,31,32]. The RIT treatment plan consisted of an
initial infusion of rituximab at a dose of 250 mg/m2 on day 1, repeated on
day 7. The second infusion of rituximab was followed by a weight-based
dose of yttrium 90-ibritumomab tiuxetan as previously described [21,22].
Patients with a pretreatment PLT count < 100,000/mL or bone marrow
lymphoma inﬁltration > 25% were not eligible for RIT. The mobilization
protocols were chemotherapy (ifosfamide, etoposide, epirubicin regimen
[33] or cyclophosphamide 7 g/m2, day 1) þ granulocyte colony-stimulating
factor (G-CSF; 5 mg/kg daily) given from day 6 after chemotherapy or G-CSF
alone (10 mg/kg daily) beginning 4 days before stem cell harvest.
Before 2008, all patients who failed the ﬁrst mobilization attempt
underwent bone marrow harvest. After 2008, the CXCR4 inhibitor plerixafor
was given at the dose of 240 mg/kg on the evening of the days before leu-
koapheresis, which was initiated approximately 10 hours later. Before being
approved in Europe, plerixafor was slated only as compassionate use from
2008 to 2010.
All patients were treated with the BEAM (BCNU, etoposide, cytosine
arabinoside, melphalan) conditioning regimen before stem cell infusion, as
previously reported [34]. G-CSF was administered to all patients to accel-
erate neutrophil recovery beginning 6 days after stem cell infusion.
Inclusion Criteria and Stem Cell Collection Procedure
Patients were considered suitable for PBSC mobilization if aged  18
years and 65 years and potentially eligible for ASCT with Eastern Coop-
erative Oncology Group  2. Additional criteria included adequate white
blood cell counts, neutrophil, PLT count, serum creatinine, and normal liver
function. In addition, all patients were assessed for cardiac and respiratory
function tests, and patients with impaired left ventricular ejection fraction
or abnormal respiratory tests were excluded. All patients signed a written
informed consent, and the protocol was carried out according to the
Declaration of Helsinki and approved by the institutional review board.
The PBSC collection procedure was initiated when CD34þ cell counts
reached to 10/mL. Double-volume leukoapheresis (two blood volume)
was used, according to the institutional guidelines, until enough stem cells
were collected: The minimum stem cell dose needed to proceed to
ASCT was 2.0  106/kg. The optimal stem cell dose was considered to be
5.0  106/kg, according to the literature [35-37]. Regarding rescue HST
harvest procedures (such as bone marrow harvest or plerixafor salvage),
although the optimal stem cell dose was still considered to be2.0 106/kg,the minimum CD34þ cell dose required to undergo ASCT was lowered to
.8 106/kg for those patients lacking valid alternative therapeutic options.Statistical Analysis
Differences in proportions between groups were evaluated by using the
chi-square test. Differences of median values of collected and reinfused
CD34þ cells between groups were calculated using the Mann-Whitney test.
Differences in engraftment kinetics between groups were calculated with
the Kaplan-Meier method [38], using the Wilcoxon rank test. Signiﬁcance
was set at P < .05.RESULTS
Impact of RIT and Other Prior Therapies on Stem Cell
Mobilization and Collection
From January 2005 to December 2012, 103 patients
affected by FL underwent PBSC mobilization in our institu-
tion. ASCT was ﬁnally performed in 97 patients. Six patients
did not undergo ASCT because of disease progression (n¼ 2),
left ventricular ejection fraction < 50% (n ¼ 2), and insufﬁ-
cient stem cell harvest (n ¼ 2). Thirteen patients included in
a phase II study received ASCT as consolidation in ﬁrst
complete response. During the same period, 211 patients
Table 1
General Patient Characteristics
Factor R-CHOP(-like) R-FM RIT P
No. of patients (%) 69 (67) 21 (20.4) 13 (12.6)
Age, median (range) 48 (27-67) 47 (35-65) 51 (36-66) .7*
Gender, M/F (%) 35/34 (50.7/49.3) 10/11 (47.6/52.4) 7/6 (53.8/46.2) .9y
Weight, median (range) 77 (50-98) 75 (47-88) 80 (52-110) .5*
Stage at diagnosis
I-II (%) 13 (18.8) 3 (14.3) 2 (15.3) .9y
III-IV (%) 56 (81.2) 18 (85.7) 11 (84.7)
Bone marrow involvement
Yes (%) 7 (10.1) 3 (23) 1 (7.7) .5y
No (%) 62 (89.9) 13 (77) 12 (92.3)
Lines of therapies before mobilization,
median (range)
1 (1-3) 2 (1-3) 2 (2-3) <.001*,z
<.001*,x
.09*,k
First line (median no. of cycles) NE
R-CHOP 51 (6 ) 2 (6) 7 (6)
R-MACOP-B 18 (12) 1 0
R-CVP 0 0 2 (6)
R-FM 0 17 (6 ) 4 (6)
RT 3 1 0
First mobilization regimen
IEVþG-CSF (%) 48 (69.5) 12 (57.1) 9 (69.2) .4y
CTX þ G-CSF (%) 18 (26.1) 6 (28.6) 2 (15.4)
G-CSF (%) 3 (4.4) 3 (14.3) 2 (15.4)
Preemptive Plerixafor 0 1 (4.8) 1 (7.7)
R-MACOP-B indicates rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin, prednisone; IEV, ifosfamide, etoposide, epirubicin; RT,
radiotherapy; CTX, high-dose cyclophosphamide; NE, not evaluated; M, male; F, female.
* Mann-Whitney test.
y Chi-square test.
z (R)-CHOP vs. (R)-FM.
x (R)-CHOP vs. RIT.
k (R)-FM vs. RIT.
Figure 2. HSC collection algorithm in the RIT group. LVEF, left ventricular
ejection fraction; CHEMO, chemotherapy.
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etan. RIT was given at disease relapse in 164 cases and as
ﬁrst-line consolidation in 47 patients enrolled in 3 phase II
studies and 1 phase III randomized trial [18,21,22,39]. Forty-
one patients had both RIT and the PBSC mobilization
procedure during their disease course, and in 13 patients the
PBSC mobilization was attempted after RIT exposure. The
study design is depicted in Figure 1.
At the time of mobilization, 69 patients had received R-
CHOP (or CHOP-like regimens), 21 patients R-FM, and 13
patients RIT with yttrium-90 ibritumomab tiuxetan at least
once earlier in the disease course. Characteristics of patients
are described in Table 1.
In the RIT group (n ¼ 13), 11 patients met the diagnosis of
FL grade I-IIIA, and 2 patients were affected by FL grade IIIB/
DLBCL. Seven patients received RIT as ﬁrst-line consolidation
and 6 patients at disease relapse. Eight patients (61%) did not
reach the minimum CD34þ cell count to undergo apheresis
(10/mL). One of these patients received plerixafor at ﬁrst
mobilization with a “just in time” approach, ﬁnally reaching
the optimum mobilization target of >5.0  106 CD34þ/kg;
thus, 6 patients (46%) ﬁnally reached the collection yield of
2.0  106 CD34þ cells/kg at ﬁrst mobilization attempt.
Considering the remaining patients who failed (n ¼ 7),
a bonemarrow harvest was attempted in 5, 2 patients had G-
CSFþ plerixafor as remobilization procedure, and 1 had both.
Remarkably, 6 additional patients (5 patients after bone
marrow harvest and 1 after G-CSF þ plerixafor) were ﬁnally
able to collect the minimum HSCs required to undergo ASCT.
Considering also the ﬁrst mobilization attempt, 2 of 3
patients rescued with plerixafor met the mobilization target
of>2.0 106 CD 34þ cells/kg. Themedian number of CD34þ
cells collected in the 7 patients undergoing salvage harvest
procedures was .95 CD34þ  106/kg (range, .72 to 3.6).
Overall, after the second/third harvest, the median value ofCD34þ cells collected increased from 1.7 to 3.3  106 CD34þ
cells/kg (range, .72 to 8.2). Finally, ASCT was successfully
performed in 10 patients (77%). Three patients did not
Figure 3. (A) Impact of prior therapies (R-CHOP versus R-FM versus RIT) on the ﬁrst PBSC mobilization attempt. (B) Impact of prior ﬂudarabine versus R-CHOP
exposure on the ﬁrst PBSC mobilization attempt in the RIT group. (C) Impact of the number of prior therapies on the ﬁrst PBSC mobilization attempt. *P < .05; **P <
.01; ***P < .001.
E. Derenzini et al. / Biol Blood Marrow Transplant 19 (2013) 1695e17011698undergo ASCT, 1 because of insufﬁcient HSC harvest, 1
because of left ventricular ejection fraction < 50%, and 1
because of disease progression. The time from RIT exposure
to PBSC mobilization (>/<12 months) did not appear to
inﬂuence the ﬁnal outcome of PBSC collection (P ¼ .14). The
HSC collection algorithm of the RIT group is depicted in
Figure 2, and detailed data of patients in the RIT group are
shown in Supplemental Table 1.
Considering the whole study cohort (N ¼ 103 patients),
the type of previous therapy signiﬁcantly affected PBSC
collection because the median CD34þ cell yield was 7.2 
106/kg in the R-CHOP group versus 4.3  106 CD34þ cells/kg
in the R-FM group versus 1.7  106 CD34þ cells/kg in the RIT
group (P ¼ .02 R-CHOP versus R-FM; P < .001 R-CHOP versus
RIT; P ¼ .02 R-FM versus RIT; Mann-Whitney test)
(Figure 3A). Interestingly, with the limit of small numbers
available, no signiﬁcant differences in PBSC mobilization
were observed in patients previously exposed to both R-FM
and RIT compared with patients treated with both R-CHOP
and RIT (Figure 3B). At ﬁrst mobilization attempt, the
collection yield of 2.0  106 CD34þ cells/kg was reached in
97% of patients (n¼ 67) in the R-CHOP group versus 76% (n¼
16) in the R-FM group versus 46% (n ¼ 6) in the RIT group.
Although the median number of prior therapies was 1 in the
R-CHOP group versus 2 in the R-FM and RIT groups, the
number of treatments received before HSC mobilization per
se did not signiﬁcantly affect the amount of PBSC collected (1
versus 2 lines: P ¼ .1; 1 versus 3 lines: P ¼ .1; 2 versus 3 lines:
P ¼ .7; MannWhitney test) (Figure 3C). Considering the totalTable 2
General Mobilization Outcome According to Prior Therapies
Factor R-CHOP (n ¼ 69)
Collected CD34þ cells, median (range) 7.2 (0-39.7)
2.0  106 CD34þ/kg (%) 67 (97)
5.0  106 CD34þ/kg (%) 45 (65)
Median days of leucoapheresis (range) 1 (1-3)
Salvage harvest procedure (%) 1 (1.5)
Patients proceeding to ASCT (%) 68 (98.5)
* Mann-Whitney test.
y Chi-square test.
z R-CHOP vs. R-FM.
x R-CHOP vs. RIT.
k R-FM vs. RIT.number of chemotherapy cycles received before mobiliza-
tion, 12 patients had6 cycles, 60 patients between 7 and 12
cycles, and 31 patients received 13 to 20 cycles. In addition,
the total number of chemotherapy cycles received before
mobilization did not affect the PBSC collection rate (0 to 6
cycles versus 7 to 12 cycles, 13 to 20 cycles, P ¼ .8, Mann
Whitney test, data not shown). Mobilization results accord-
ing to prior therapies are summarized in Table 2 and Figure 3.
Impact of RIT and Other Prior Therapies on Engraftment
after ASCT
Because a concern about PBSC harvest after RIT exposure
is the quality of HSCs collected, we evaluated the function-
ality of the reinfused stem cells by assessing the engraftment
parameters. Overall, 97 patients underwent ASCT after HSC
collection. Stem cell source were PBSC in 91 patients (94%),
bone marrow in 5 (5%), and both in 1 (1%). The median
number of reinfused CD34þ cells was 4.4 for the R-CHOP
group versus 3.4 for the R-FM group versus 2.6 for the RIT
group (P < .01 R-CHOP versus RIT; P ¼ .07 R-CHOP versus R-
FM; P ¼ .08 R-FM versus RIT). General data on ASCT and
engraftment in the 3 groups are shown in Table 3. Of note
70% of patients (7/10) in the RITgroup received>2.0106/kg
CD34þ cells (Supplemental Table 1).
Median time to ANC> 500/mL and PLT recovery> 20,000/
mL was 10 and 11 days, respectively, from stem cell infusion in
all groups. Using the Kaplan-Meiermethod and theWilcoxon
rank test, we did not ﬁnd a statistically signiﬁcant difference
between the two chemotherapy arms and the RIT armR-FM (n ¼ 21) RIT (n ¼ 13) P
4.3 (0-13.9) 1.7 (0-8.2) .02*,z
<.0001*,z
.02*,k
16 (76.2) 6 (46) <.001y
9 (42.8) 2 (15) <.01y
1 (1-3) 2 (1-3) .03*,z
<.001*,x
.09*,k
5 (24) 8 (61.5) <.001y
19 (90.5) 10 (76.9) .007y
Table 3
Characteristics of ASCT and Engraftment According to Prior Therapies
ASCT R-CHOP (n ¼ 68) R-FM (n ¼ 19) RIT (n ¼ 10) P
Reinfused CD34þ cells, median (range) 4.4 (1.2-12.2) 3.4 (1.2-8.3) 2.6 (0.7-4.2) .07*,x
<.01*,k
.08*,{
Stem cell source (%)
PBSC 68 (100) 18 (94.8) 6 (60)
Bone marrow 0 (0) 1 (5.2) 4 (40) <.001y
Both 0 (0) 0 (0) 1 (10)
Days to neutrophil recovery > 500/mL, median (range) 10 (7-18) 10 (8-13) 10 (8-24) .1z
Days to PLT recovery > 20,000/mL, median (range) 11 (9-19) 11 (9-25) 11 (10-180) .1z
* Mann-Whitney test.
y Chi-square test.
z Wilcoxon rank test.
x (R)-CHOP vs. (R)-FM.
k (R)-CHOP vs. RIT.
{ (R)-FM vs. RIT.
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Only the absolute number of reinfused CD34þ cells signiﬁ-
cantly affected ANC and PLTengraftment (Figure 4B). Of note,
considering the RIT group, in 6 of 7 patients (86%) who were
reinfused with more than 2.0  106 CD34þ cells/kg, the
hematologic recovery was fast and complete (Figure 4C).
These ﬁndings indicate that RIT exposure per se does not
impair PLT and ANC engraftment and thus the quality of
collected stem cells. No differences in the incidence of febrile
neutropenia were noted across the 3 groups (42% in theFigure 4. (A) Time to ANC (500/mL) and PLT recovery (20,000/mL) in the chemothe
ANC (500/mL) and PLT recovery (20,000/mL) in patients reinfused with <2.0  106
CD34þ cells (total n ¼ 88). (C) Time to ANC (500/mL) and PLT recovery (20,000/mL) i
for patients reinfused with >2.0  106/kg CD34þ cells (total n ¼ 88).R-CHOP group, 33% in the R-FM group, 38% in the RIT group,
P ¼ NS).
Late Hematologic Toxicity and Secondary Neoplasms
All patients had a complete neutrophil recovery after
ASCT. PLT recovery was complete (150,000/mL) in 93 of 97
patients. One patient in the R-CHOP, 1 in the R-FM, and 2 in
the RIT group had an incomplete PLT recovery.
We observed only 1 case of secondary acute myeloid
leukemia developing in a patient exposed in sequence torapy (CHT) group (n ¼ 87) compared with the RIT group (n ¼ 10). (B) Time to
/kg CD34þ cells (n ¼ 9) compared with patients reinfused with >2.0  106/kg
n the chemotherapy (CHT) group (n ¼ 81) compared with the RIT group (n ¼ 7)
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48 months after ASCT. In this patient PBSCs were collected
before RIT and ﬂudarabine exposure. Median follow-up was
61 months in the R-CHOP group versus 64 months in the
R-FM group versus 58 months in the RIT group (P ¼ NS). No
myelodysplastic syndromes were documented in any treat-
ment group.
DISCUSSION
This is the ﬁrst study investigating the effect of RIT on HSC
mobilizationwith respect to other therapies in FL. These data
show that although prior RIT signiﬁcantly impairs PBSC
mobilization compared with other chemotherapy regimens,
HSC harvest after RIT exposure is feasible, allowing most
patients to undergo ASCT with a salvage harvest/remobili-
zation procedure. In this light, the activity of the CXCR4
inhibitor plerixafor, which was used with G-CSF in 3 cases,
was particularly promising, allowing 2 patients to collect
 2  106 CD34þ cells/kg without the need of performing
a bone marrow harvest. Although the proportion of patients
undergoing ASCT was slightly higher in the CHOP and ﬂu-
darabine groups, notably 77% of patients (10/13) in the RIT
group could ﬁnally undergo ASCT, and 2 of 3 patients were
not able to proceed to ASCT for causes unrelated to HSC
collection. The time from RIT exposure to PBSC mobilization
did not appear to inﬂuence the ﬁnal outcome of PBSC
collection, and, interestingly, patients previously treated
with both ﬂudarabine and RIT retained the possibility to
mobilize PBSC.
Although there was a signiﬁcant reduction in PBSC
collection in patients previously treated with ﬂudarabine
comparedwith CHOP, in this study 76% of patients previously
exposed to ﬂudarabine reached the collection yield of 2 
106 CD34þ cells/kg. Interestingly, all patients in the R-FM
group received a cumulative ﬂudarabine dose higher than
150 mg/m2, which was recently reported to be the threshold
for a detrimental effect on PBSC mobilization and long-term
toxicity in FL patients undergoing ASCT [13]. The higher rate
of mobilization success reported in the present study after
ﬂudarabine treatment with respect to other reports could be
explained by the fact that the vast majority of patients were
mobilized with chemotherapy plus G-CSF, suggesting that
the mobilization schedule (chemotherapy þ G-CSF versus
G-CSF alone) could overcome the adverse effects of prior
ﬂudarabine exposure. Although patients in the RIT and R-FM
groups received more therapy at the time of mobilization
(median of 2 lines in the RIT and in R-FM arms versus 1 line in
the R-CHOP arm), the amount of lines and cycles of therapy
received before mobilization per se did not signiﬁcantly
affect the PBSC mobilization rate. Regarding engraftment
after ASCT, the CD34þ cell dose was the most important
factor affecting engraftment kinetics, and most RIT-exposed
patients who were reinfused with 2  106 CD34þ cells/kg
had a fast and complete hematologic recovery after ASCT.
Taken together, these ﬁndings indicate that the quality of
collected HSCs is not affected by previous RIT exposure.
Notably, we observed only 1 case of secondary acute myeloid
leukemia (.9%) in a heavily pretreated patient.
In conclusion, these data suggest that with current
mobilization regimens most patients previously exposed to
RIT retain the possibility to collect enough HSC to undergo
ASCT, without signiﬁcant increases in short- and long-term
hematologic toxicities. Plerixafor should be recommended
for HSC mobilization in all post-RIT patients due to the high
rate of initial mobilization failure.This is the ﬁrst study addressing the effect of prior RIT on
HSC mobilization and ASCT. Here we show that although the
mobilization rate is signiﬁcantly impaired in patients previ-
ously treated with RIT, most patients retain the possibility of
undergoing ASCT after a salvage HSC harvest.
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